Transfer of the herpes simplex virus thymidine kinase (HSVtk) gene, followed by administration of ganciclovir (GCV), generates the "bystander effect," in which HSVtk-negative wild-type cells are killed by GCV, as are HSVtk-expressing cells. Our previous study demonstrated that intracranial 9L gliomas could be efficiently treated due to this bystander effect by injecting the 9L glioma cells transduced with the HSVtk gene in the vicinity of the preimplanted wild-type 9L glioma and then administering GCV. For a possible clinical application of the bystander effect-mediated cell killing, we tested HSVtk gene-transduced allogeneic C6 glioma cells (C6tk) instead of syngeneic 9L glioma cells transduced with the HSVtk gene. Fisher rats were implanted intracranially with wild-type 9L glioma cells, subsequently injected with C6tk cells at the same brain coordinate, and thereafter treated with GCV or saline. When the rats were treated with GCV, a significant retardation of tumor growth was observed by serial magnetic resonance imaging, although this growth retardation was less prominent than that observed with 9L glioma cells transduced with the HSVtk gene; consequently, survival was prolonged (P Ͻ .01). Tumors that received C6tk cells contained almost no HSVtk-positive cells after treatment with GCV. Rejection of allogeneic tumor cells, although possibly incomplete in the brain, can also contribute to the safety of this therapeutic strategy. Cancer Gene Therapy (2000) 7, 947-953
T ransfer of the herpes simplex virus thymidine kinase (HSVtk) gene, followed by administration of ganciclovir (GCV), generates the "bystander effect," in which HSVtk-negative wild-type (wt) cells as well as HSVtkexpressing cells are killed by GCV. In our previous rat study, tumor cells transduced with the HSVtk gene (effector cells) were injected intracranially in the vicinity of the preimplanted wt tumor (target cells); next, GCV was administered, and we observed that tumors were efficiently treated through the bystander effect. 1 However, it is not practical to treat a brain tumor with the same patient's cells as effectors in a clinical condition, because the tumor cells obtained by the surgery have to be transduced with the HSVtk gene, cultured, and then returned to the patients during another surgery. In the present study, C6 rat brain tumor cells of Wistar rat origin transduced with the HSVtk gene (C6tk) were used as effector cells to treat 9L brain tumors in Fisher rats.
This study consisted of three portions. First, we tested whether allogeneic C6tk cells implanted in the Fisher rat brain were eliminated by the administered GCV or due to rat immune reactions. Second, the bystander effect between C6tk and wt 9L (9Lwt) was evaluated using magnetic resonance imaging (MRI) in the coimplantation model in the Fisher rat brain. Third, we tested the possibility of treatment of preimplanted 9Lwt tumors by the subsequent administration of C6tk and GCV.
MATERIALS AND METHODS

Establishment of C6 glioma cells with the HSVtk gene
C6 glioma cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf sera. The retrovirus vector LXSN 2 harboring the HSVtk gene 3 was kindly provided by Genetic Therapy Inc. (Gaithersburg, Md). C6 cells were incubated with supernatants of the HSVtk retrovirus-producing cells (PA317) in the presence of 8 g/mL polybrene (Aldrich, Milwaukee, Wis) for several hours. After washing, the cells were maintained with the medium for 1 day and then drug selection with 400 g/mL G418 (Life Technologies, Gaithersburg, Md) was started. The drug-resistant C6 cells were cloned and tested for sensitivity to GCV (F. Hoffmann-La Roche, Basel, Switzerland). The clone, having high GCV sensitivity and the same in vitro proliferative rate as 9Lwt cells, was used for additional experiments (C6tk cells).
Tumor inoculation in Fisher rats
All the experiments were performed on 7-to 8-week-old male Fisher 344 rats that were syngeneic to 9L cells but allogeneic to C6 cells; rats weighed between 200 and 240 g at the time of tumor inoculation. The method of intracranial tumor inoculation has been described previously. 4 Briefly, a burrhole was placed 4 mm posterior to bregma and 3 mm right to midline using a stereotaxic apparatus (Narishige Scientific Instrument Laboratory, Tokyo, Japan) under pentobarbital anesthesia (50 mg/kg intraperitoneally (i.p.); next, a 25-gauge needle was inserted 4 mm ventral from dura, where tumor cells were inoculated using a 50-L microsyringe (Hamilton Company, Reno, Nev) and a microinjector (Harvard Apparatus, South Natick, Mass).
C6tk tumor cells in Fisher rats
A total of 12 rats were injected intracranially with 10 5 C6tk cells in 10 L of medium for 5 minutes. The needle was kept in place for one additional minute before removal. The animals were kept under ordinary laboratory conditions thereafter, and no steroids or antibiotics were used. A total of 3 of 12 rats were also implanted subcutaneously (s.c.) with 10 5 C6tk cells in 10 L of medium in the scalp on the opposite side (C6/SC). Of the other nine animals, five rats were given 15 mg/kg GCV i.p. twice daily (30 mg/kg/day) from day 7 to day 20 (C6/GCV), and the other four control rats were given physiological saline (C6/PS).
Animals that rejected C6tk tumors received another intracranial inoculation of wt C6 cells (10 5 ) at the same coordinate of the other side of the initial inoculation on day 100.
In vivo bystander effect between C6tk and 9Lwt cells 
Measurement of tumor size using MRI
Animals anesthetized with 50 mg/kg pentobarbital were placed on a surface coil. After injection of 0.2 mL of gadoliniumdiethylenetriaminepentaacetic acid (Gd-DTPA) (0.8 -1.0 mL/ kg), coronal T1-weighted images (repetition time, 500 milliseconds; echo time, 11 milliseconds; 3-mm thickness; gapless) were obtained with a 1.5-tesla MR device (Signa Advantage, General Electric, Milwaukee, Wis). Measurement of tumor size (mm 3 ) was calculated as the sum of the Gd-enhanced portion as judged by each MR imaged area (mm 2 ) times imaged thickness. MRI studies were started on day 7 and continued every 7 days until day 21 and at proper intervals thereafter.
Detection of HSVtk-positive cells by polymerase chain reaction (PCR)
DNA was obtained from tumors with proteinase K digestion and phenol extraction. A PCR to detect the HSVtk sequence was performed with the same 5Ј primer and two different respective 3Ј primers. 5Ј-CATCAACACGCGTCTGCGTTC-3Ј (sense primer) and both 5Ј-CTCGGGTACGTAGAC-GATATC-3Ј and 5Ј-TAAGTCATCGGCTCGGGTACG-3Ј (antisense primers) were synthesized based on the published sequence. 5 The reaction was carried according to a standard procedure that has been described previously. 6 Briefly, 1 g of DNA was mixed with Taq DNA polymerase (Perkin-Elmer, Norwalk, Conn), 0.2 M primers, 200 M deoxynucleoside triphosphate, 10 mM tris(hydroxymethyl)aminomethane-HCl (pH 8.3), and 50 mM KCl. Thirty cycles of PCR consisted of denaturation at 94°C for 1 minute, annealing at 59°C for 1 minute, and extension at 72°C for 2 minutes. The final PCR products were subjected to 2% agarose gel electrophoresis to detect the expected bands (either 231 bp or 242 bp, respectively). To determine the sensitivity of this PCR, DNAs from HSVtk-positive and HSVtk-negative 9L cells were mixed at various proportions and also amplified as described above.
RESULTS
C6 tumor in Fisher rats
Two of four rats from the C6tk/PS group that were not implanted s.c. with tumors and were not given GCV developed intracranial tumors and died (Table 1) . One rat survived 20 days and the other rat survived 21 days. The other 10 rats rejected C6tk tumors (Table 1) . In these rats, a Gd-DTPA-enhanced mass was demonstrated by MRI until day 14 but disappeared at day 21 (Fig 1) . All of these rats survived for Ͼ100 days and rejected the subsequent challenge of wt C6 cells ( Table   Table 1 In vivo bystander effect between C6tk and 9Lwt cells We implanted the mixed population of 9Lwt and C6tk cells to examine whether an in vivo bystander effect could be achieved. Sequential MR images of representative rats in the saline-and GCV-injected groups are shown in Figure 2 . All of the rats in the saline group had progressive tumor growth and died within 24 days (21.8 Ϯ 1.6 days, mean Ϯ SD, Table 2 ). This growth rate of the tumors in the rats treated with saline was not different from that seen for the rats implanted with 1 ϫ 10 5 9Lwt cells alone and treated with either saline or GCV in our previous study, 4 although the total number of implanted cells was doubled in the present study (2 ϫ 10 5 ). However, retardation of tumor growth or even decrease in tumor volume was observed in the rats treated with GCV (Fig 3) , and all rats in this group survived for Ͼ30 days (38.4 Ϯ 7.2 days, P Ͻ .01 as compared with the saline group, Table 2 ). If GCV exclusively killed C6tk cells and the bystander effect was not achieved, the tumor growth should be the same as that in rats implanted with 9Lwt cells alone and treated with GCV. Therefore, the results indicated that a signif- icant bystander effect was elicited between 9Lwt and C6tk cells in the brains of immunocompetent rats.
To examine the presence of the HSVtk gene in the tumors derived from the mixed population, two kinds of PCRs using two different 3Ј primers were performed. The results were in agreement in both PCRs, in which 0.001% of HSVtk-positive cells in a HSVtk-negative population could be detected. In the saline-injected groups, three of five tumors obtained at the time of animal death contained HSVtk-positive cells; in the GCV-treated group, no HSVtk-positive cells were detected in the tumors (Table 3) .
TK cell therapy
Saline-treated rats died of intracerebral tumor growth between day 17 and day 23 postimplantation, irrespective of the amounts of C6tk cells implanted. The survival days were 21.3 Ϯ 1.5 days (mean Ϯ SD) in the salinetreated animals in group I and 19.0 Ϯ 1.8 days in group II (Table 2) ; this was not different from the survival days in rats implanted with 1 ϫ 10 5 9Lwt cells alone and treated with either saline or GCV. 4 The mean survival days in group I and II animals treated with GCV were 26.5 Ϯ 0.6 and 28.8 Ϯ 4.8 days, respectively, which was significantly longer than those of corresponding salinetreated animals (P Ͻ .01, Student's t test, Table 2 ). When 10 5 9Lwt cells were implanted, the rats developed intracranial tumors and all of the animals were killed. On day 7 postimplantation, the presence of a small tumor of ϳ10 mm 3 was confirmed in every tested animal by Gd-DTPA-enhanced MRI. On day 14, the size of the tumors progressively increased. The growth of the tumor in the GCV-treated groups was markedly suppressed compared with that in the saline-treated group during GCV administration, although tumor regression was not observed in any of the GCV-treated rats (Figs 4  and 5) .
In the saline-injected groups, half of the rat tumors in group I (one of two tumors) and group II (two of four tumors) contained HSVtk-positive cells at the time of death, and the other half did not. In the GCV-treated group, PCR analysis detected HSVtk-positive cells in one of eight tumors at the time of animal death, although the signal was extremely weak (Table 3) .
DISCUSSION
In our previous experiment of HSVtk/GCV gene therapy, we introduced a treatment modality for brain tumors using the bystander effect between pre-existing wt tumor cells and injected HSVtk gene-transduced tumor cells in the vicinity of the pre-existing tumor.
1 A retroviral-mediated gene delivery system, which has already been tested in clinical application, 7 appears to have several disadvantages, including a risk of replication-competent virus produced by recombination and generation of mutagenesis as well as its low efficiency of transduction. The use of retrovirus-producing fibroblasts for the purpose of treatment of human gliomas also has a disadvantage in that the fibroblasts do not migrate into and mix well with glioma cells, which tend to invade and spread into surrounding brain tissues. A recent experimental study using multiple injections of murine RSV-M glioma cells showed that the glioma cells injected in a second inoculum, unlike virus-producing fibroblast cells, migrated along the corpus callosum by the same route as the initially implanted glioma cells, and many had caught up with the glioma cells initially implanted. 8 The study and our previous study also demonstrated a significant growth suppression of initially implanted glioma cells by the therapeutic injection of HSVtk-positive tumor cells followed by GCV treatment. These experimental findings suggest that tumor cells infiltrate into pre-existing tumor masses more efficiently than fibroblasts, and therefore are more suitable for the treatment of human gliomas.
In both of the in vivo experiments using HSVtkpositive tumor cells and GCV cited above, The present rat study implicates a possible TK cell therapy for human gliomas. HSVtk gene-transduced human glioma cells are implanted into the resected sites at the time of debulking surgery, and the residual tumor cells remaining in the cavity can be treated by subsequent intravenous administration of GCV in a certain interval. The fact that HSVtk-positive cells were barely detected in the tumors of the rat treated with GCV demonstrated the safety of this treatment modality. Immunological rejection of allogeneic cells by a host immunological response provides another safety valve for human clinical trials.
Allogeneic tumor cells, when implanted in the brain, can kill the injected rats. The brain is regarded as an "immunologically privileged" site, 14 and in fact half of the rats could not reject allogeneic C6 tumor cells (Table  1 ). However, s.c. implantation of C6tk tumor cells did not allow immunological tolerance to the C6tk cells implanted intracranially; consequently, C6tk brain tumors were rejected. Moreover, intracranial implantation of C6 cells to the rats that had rejected C6tk cells did not result in tumor formation. Thus, the antitumoral effect caused by the immune system of the host, in certain cases, may not be enough to eliminate allogeneic tumor cells. However, the brain is not a completely immunologically privileged site. An appropriate stimulation of the immune system of the host, such as s.c. implantation, can activate defense mechanisms in the brain. These incomplete immunological responses in the brain favor the use of allogeneic cells. Implanted HSVtk-positive allogeneic cells can penetrate into residual tumors; in addition, an activated host immune system as a result of GCV-mediated cell death can eliminate allogeneic cells even if the implanted cells may have lost the HSVtk gene. ) and were injected with GCV or saline from day 7 to day 20.
However, the tumoricidal bystander effect on 9Lwt cells by the combination of C6tk cells and GCV was not as strong as that caused by the combination of 9L glioma cells transduced with the HSVtk gene and GCV in Fisher rats. Although this study shows that the in vivo bystander effect-mediated therapy is still present even when HSVtk gene-transduced cells are allogeneic, application of TK cell therapy for human gliomas requires improvement to achieve a more efficient bystander effect. Intercellular communication mediated by gap junctions has been shown to have an important role in the bystander effect. 10, 12, 13 Because C6 cells exhibit a low level of intercellular communication by gap junctions, 13 modification of connexin gene expression could induce a more potent bystander effect. A combined therapy using cytokine genes to stimulate immune system of the host and further enhance the effect of the therapy is also being investigated. 16 -21 
